How to Get Vyleesi (Bremelanotide) in Nebraska

What Is Vyleesi and Who Qualifies for It?

Vyleesi (bremelanotide) is the only FDA-approved on-demand injectable treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug activates melanocortin-4 receptors in the central nervous system, which are involved in the neural pathways governing sexual desire. It is not indicated for postmenopausal women, for men, or for enhancing sexual performance in the absence of an HSDD diagnosis.

FDA Approval and Trial Evidence

The FDA approved bremelanotide in June 2019 based on the RECONNECT trials, two randomized, double-blind, placebo-controlled phase 3 studies enrolling 1,247 premenopausal women with HSDD. At 24 weeks, women receiving bremelanotide 1.75 mg reported a statistically significant increase in desire (measured by the Female Sexual Function Index desire domain) and a meaningful reduction in distress (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) compared with placebo [1]. The prescribing label notes a treatment effect of approximately 0.5 points on the FSFI desire domain and a reduction of roughly 11 points on the FSDS-DAO total score [2].

Diagnostic Criteria

HSDD is defined by the DSM-5 under Female Sexual Interest/Arousal Disorder. A qualified clinician must confirm that the patient has persistently reduced or absent sexual desire that causes marked personal distress, is not better explained by another psychiatric or medical condition, and is not due to substance use or relationship factors. Lab work (discussed below) helps rule out contributing medical causes before a prescription is written.

Nebraska Prescribing Rules for Vyleesi

Nebraska law allows physicians (MDs and DOs), nurse practitioners, and physician assistants to prescribe Vyleesi. The state does not impose any special drug-specific restrictions on bremelanotide beyond standard controlled-substance and prescribing regulations. Because Vyleesi is not a scheduled substance, any licensed prescriber with authority to write prescriptions can issue one.

Telehealth Prescribing in Nebraska

Nebraska has permitted telehealth prescribing since the passage of the Telehealth Act (Neb. Rev. Stat. §§ 71-8501 to 71-8511), and post-pandemic legislative updates made many expanded telehealth allowances permanent. A prescriber licensed in Nebraska (or holding a valid interstate compact license) may evaluate a patient via synchronous audio-video visit and write a Vyleesi prescription without a prior in-person exam [3].

This means a patient in Omaha, Lincoln, Grand Island, or any rural Nebraska community can complete an HSDD evaluation from home. The telehealth provider verifies the patient's identity, reviews labs, documents diagnostic criteria, and transmits the prescription electronically to a pharmacy of the patient's choice.

MD, NP, and PA Prescribing Scope

Nebraska NPs have full practice authority under the state's Nurse Practice Act, meaning they can independently diagnose HSDD and prescribe Vyleesi without a collaborating physician agreement [4]. PAs in Nebraska must maintain a practice agreement with a supervising physician, but that agreement routinely covers prescribing non-controlled medications like bremelanotide. For practical purposes, patients can see any of these three provider types.

Step-by-Step: Getting a Vyleesi Prescription in Nebraska

The process from initial inquiry to autoinjector in hand typically takes 1 to 3 weeks, depending on insurance authorization timelines and pharmacy stocking.

Step 1: Clinical Evaluation

Schedule either an in-person appointment or a telehealth visit with a prescriber experienced in sexual medicine or women's health. During the visit, expect a focused sexual health history, a mental health screening, and a review of current medications. The clinician will apply DSM-5 criteria for Female Sexual Interest/Arousal Disorder. Short. Direct. No ambiguity about what the visit involves.

Step 2: Pre-Prescription Lab Work

No specific lab panel is FDA-mandated before starting Vyleesi, but most prescribers order baseline labs to exclude endocrine or metabolic contributors to low desire. A standard pre-Vyleesi panel typically includes:

• Thyroid function (TSH, free T4) to rule out hypothyroidism
• Prolactin to screen for hyperprolactinemia
• Total and free testosterone because low androgen levels can contribute to HSDD
• CBC and CMP as a general health screen
• Hemoglobin A1c or fasting glucose if metabolic syndrome is suspected

Any CLIA-certified lab in Nebraska (Quest, LabCorp, or hospital-based labs) can draw these panels. Results are typically available within 24 to 48 hours, and telehealth providers often supply a lab order electronically before the appointment so patients can walk in to a draw site the same week.

Step 3: Prescription and Pharmacy Selection

Once the prescriber confirms HSDD and reviews labs, they transmit the prescription electronically. Patients choose between:

• Retail pharmacy (CVS, Walgreens, or independent Nebraska pharmacies that stock specialty items)
• Specialty pharmacy used by the insurer for prior-auth fulfillment
• 503A compounding pharmacy licensed in Nebraska for compounded bremelanotide (discussed below)

Most retail chains do not stock Vyleesi on the shelf as a standard item. Expect a 2- to 5-day order window at a retail pharmacy, or immediate shipping from a specialty pharmacy once authorization is in place.

Step 4: First Dose Administration

Vyleesi is delivered via a single-use autoinjector. The first injection should ideally be administered in a clinical setting so the provider can monitor for transient side effects, specifically nausea and flushing, which affected 40% and 20% of RECONNECT participants, respectively [1]. After a supervised first dose, patients self-administer subsequent doses at home.

Insurance Coverage and Prior Authorization in Nebraska

Coverage varies sharply by payer, and Nebraska Medicaid does not cover Vyleesi. Commercial plans often impose prior authorization (PA) before approving the drug.

Commercial Insurance

Most Nebraska-market commercial plans from carriers like Blue Cross Blue Shield of Nebraska, Medica, and UnitedHealthcare will consider Vyleesi coverage after PA. A 2021 claims analysis published in the Journal of Managed Care & Specialty Pharmacy found that only about 30% of initial Vyleesi prior-authorization requests were approved on the first submission across national commercial plans [5]. Denials frequently cited incomplete documentation or failure to try flibanserin first.

What Prior Authorization Requires

Nebraska insurers typically request the following documentation:

1. Confirmed HSDD diagnosis with DSM-5 criteria documented in the clinical note
2. Duration of symptoms, generally 6 months or longer
3. Statement that the condition causes clinically significant distress (patient-reported outcome scores help)
4. Trial-and-failure documentation for flibanserin (Addyi), if the plan requires step therapy
5. Lab results ruling out organic causes
6. Prescriber attestation that the patient is premenopausal and not using the drug off-label

Appeals succeed more often when the prescriber includes validated questionnaire scores (FSFI, FSDS-DAO) and a detailed letter of medical necessity. The entire PA process takes 5 to 15 business days for most Nebraska plans.

Nebraska Medicaid

Nebraska Medicaid, administered under the Heritage Health managed care program, does not include Vyleesi on its preferred drug list. Patients enrolled in Medicaid who have an HSDD diagnosis may request an exception through the Medicaid prior-authorization process, but approval rates for non-formulary sexual health medications in state Medicaid programs nationally remain below 10%, according to data from the Kaiser Family Foundation [6].

Medicare

Medicare Part D plans do not cover Vyleesi because the drug's labeled population is premenopausal women. Patients under 65 with Medicare due to disability may occasionally attempt PA, but these claims are almost universally denied given the indication.

Cost-Saving Strategies for Nebraska Patients

The average cash price for a 4-autoinjector carton of Vyleesi is between $800 and $1,000. Several cost-reduction pathways exist.

Manufacturer Savings Program

AMAG Pharmaceuticals offers a co-pay savings card for commercially insured patients, which can reduce out-of-pocket costs to as little as $0 per fill for eligible patients. Uninsured patients may qualify for patient assistance programs that provide the drug at no cost, subject to income verification. Check the Vyleesi official prescribing information and resources page or call the manufacturer directly for current program terms [2].

503A Compounding in Nebraska

Nebraska's Board of Pharmacy licenses 503A compounding pharmacies that can prepare bremelanotide formulations when a patient-specific prescription is provided. Compounded bremelanotide may cost 40% to 60% less than the branded autoinjector, though the product will be dispensed as a vial-and-syringe kit rather than a pre-filled autoinjector. The FDA's guidance on 503A compounding outlines the legal framework that permits pharmacies to compound copies of commercially available drugs under certain conditions [7].

Patients should confirm that their 503A pharmacy:

• Holds a current Nebraska Board of Pharmacy compounding license
• Sources bremelanotide from an FDA-registered bulk chemical supplier
• Conducts potency and sterility testing on finished preparations
• Ships with appropriate cold-chain handling if needed

Prescription Discount Cards

GoodRx, RxSaver, and similar aggregators occasionally list discounted Vyleesi pricing at Nebraska pharmacies. Prices fluctuate, but discounts of 15% to 25% off the average wholesale price are common.

Telehealth Platforms That Prescribe Vyleesi to Nebraska Patients

Several national telehealth platforms serve Nebraska patients seeking HSDD treatment. When choosing a telehealth provider, verify three things: the prescriber is licensed in Nebraska, the platform handles prior authorization, and the service coordinates specialty pharmacy delivery.

What to Expect from a Telehealth Visit

A typical Vyleesi telehealth consultation lasts 20 to 30 minutes. The clinician will ask about the onset and duration of desire changes, relationship context, mood symptoms, medication list, and any prior sexual health treatments. Most platforms accept lab results from the patient's local facility and do not require a separate blood draw through a proprietary lab.

Delivery Timelines

After a telehealth visit, the prescription is transmitted the same day. If no prior authorization is needed (cash-pay or pre-approved plan), a specialty pharmacy can ship to a Nebraska address within 2 to 4 business days. When PA is required, add 5 to 15 business days to that timeline. Rural Nebraska addresses served by USPS may add one additional transit day compared with Omaha or Lincoln metro deliveries.

Side Effects and Monitoring

The most common adverse events reported in the RECONNECT trials were nausea (40.0% vs. 1.3% placebo), flushing (20.3% vs. 1.3%), injection-site reactions (5.4%), and headache (11.3% vs. 6.5%) [1]. Nausea tends to diminish with repeated dosing. The FDA label carries a warning about transient blood pressure increases: in clinical trials, systolic BP rose by an average of 2.5 mmHg and diastolic by 1.5 mmHg within 2 to 3 hours of injection [2].

Who Should Not Use Vyleesi

Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease due to the transient pressor effect. The prescribing label also advises against use in patients at high risk for cardiovascular events. A baseline blood pressure reading at the initial visit is standard before prescribing.

Skin Hyperpigmentation

Focal darkening of the gums, face, or breasts occurred in roughly 1% of trial participants. The FDA recommends that patients with darker baseline skin pigmentation be counseled about this risk and that treatment be discontinued if unwanted hyperpigmentation develops [2].

Follow-Up Schedule

Most Nebraska prescribers recommend a follow-up visit 4 to 8 weeks after starting Vyleesi to assess efficacy, nausea tolerance, and blood pressure. After that, visits every 6 to 12 months are standard. Telehealth follow-ups are appropriate for stable patients.

How Vyleesi Compares to Flibanserin (Addyi) for Nebraska Patients

Flibanserin is the only other FDA-approved HSDD treatment for premenopausal women. It is a daily oral pill rather than an on-demand injection. A 2020 network meta-analysis in JAMA Internal Medicine found that both drugs produced modest but statistically significant improvements in desire, with bremelanotide showing a numerically larger effect size on desire endpoints in the RECONNECT trials compared with flibanserin's BEGONIA, DAISY, and VIOLET trials [8].

Key practical differences for Nebraska patients:

| Factor | Vyleesi (bremelanotide) | Addyi (flibanserin) | |---|---|---| | Dosing | On-demand, subcutaneous injection | Daily oral tablet | | Alcohol restriction | None | Absolute contraindication with alcohol | | Onset | 45 minutes before activity | Weeks of daily dosing for full effect | | Common side effect | Nausea (40%) | Dizziness, somnolence | | REMS program | No | Yes (prescriber certification required) | | 503A compounding option in NE | Yes | Yes |

For Nebraska patients who drink socially, Vyleesi's lack of an alcohol interaction may be the deciding factor.

Dr. Sheryl Kingsberg, a clinical psychologist and researcher on the RECONNECT trials, has stated: "Having an on-demand option is meaningful for women who do not want to take a daily medication for a condition that is episodic by nature" [1].

The Endocrine Society's 2019 clinical practice guideline on HSDD management notes that pharmacotherapy should be considered after psychosocial and relationship factors have been addressed, and that both bremelanotide and flibanserin are reasonable first-line options depending on patient preference [9].